Literature DB >> 29368145

Combination of Oxaliplatin and Vit.E-TPGS in Lipid Nanosystem for Enhanced Therapeutic Efficacy in Colon Cancers.

Yanlei Wang1, Xiang Zhang1, Wenqiang Zhang1, Hao Dong1, Wenjie Zhang1, Jiajia Mao1, Yong Dai2.   

Abstract

PURPOSE: The main aim of present study was to prepare the oxaliplatin (OXL)-loaded D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS)-based lipid nanoparticles to enhance the anticancer effect in colon cancer cells.
METHODS: The nanoparticles were nanosized and spherical shaped and exhibited controlled release kinetics. Flow cytometer and confocal laser scanning microscopy (CLSM) showed a remarkable uptake of nanoparticles in cancer cells in a time-dependent manner.
RESULTS: The presence of TPGS remarkably increased the anticancer effect of OXL in HT-29 colon cancer cells. The IC50 value of free OXL was 4.25 μg/ml whereas IC50 value of OXL-loaded TPGS-based lipid nanoparticles (OXL/TLNP) was 1.12 μg/ml. The 3-fold lower IC50 value of OXL/TLNP indicates the superior anticancer effect of nanoparticle-based OXL. Consistently, OXL/TLNP induced a remarkable apoptosis of cancer cells. Approximately, ~52% of cells were in early apoptosis phase and ~13% of cells were in late apoptosis phase indicating the potent anticancer effect of the formulations. The findings from this study provide novel insights into the use of TPGS and lipid nanoparticle together for the better antitumor effect in colon cancers. Future studies will involve the detailed in vitro and in vivo studies on clinically relevant animals.

Entities:  

Keywords:  antitumor efficacy; apoptosis; colon cancer; nanoparticles; oxaliplatin

Mesh:

Substances:

Year:  2018        PMID: 29368145     DOI: 10.1007/s11095-017-2297-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

Review 1.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.

Authors:  H Maeda
Journal:  Adv Enzyme Regul       Date:  2001

Review 2.  Cellular and molecular pharmacology of oxaliplatin.

Authors:  Eric Raymond; Sandrine Faivre; Stephen Chaney; Jan Woynarowski; Esteban Cvitkovic
Journal:  Mol Cancer Ther       Date:  2002-01       Impact factor: 6.261

3.  Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan.

Authors:  T Ramasamy; H B Ruttala; J Y Choi; T H Tran; J H Kim; S K Ku; H G Choi; C S Yong; J O Kim
Journal:  Chem Commun (Camb)       Date:  2015-04-04       Impact factor: 6.222

Review 4.  Smart chemistry-based nanosized drug delivery systems for systemic applications: A comprehensive review.

Authors:  Thiruganesh Ramasamy; Hima Bindu Ruttala; Biki Gupta; Bijay Kumar Poudel; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  J Control Release       Date:  2017-05-02       Impact factor: 9.776

5.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

Review 6.  Inflammation and colon cancer.

Authors:  Janos Terzić; Sergei Grivennikov; Eliad Karin; Michael Karin
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

7.  Capecitabine as adjuvant treatment for stage III colon cancer.

Authors:  Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

8.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

Authors:  J M Woynarowski; W G Chapman; C Napier; M C Herzig; P Juniewicz
Journal:  Mol Pharmacol       Date:  1998-11       Impact factor: 4.436

9.  Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.

Authors:  Yingzhe Wang; Wei Fan; Xin Dai; Usha Katragadda; DeAngelo Mckinley; Quincy Teng; Chalet Tan
Journal:  Mol Pharm       Date:  2014-03-10       Impact factor: 4.939

10.  Development and evaluation of vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate-mixed polymeric phospholipid micelles of berberine as an anticancer nanopharmaceutical.

Authors:  Roger Shen; Jane J Kim; Mingyi Yao; Tamer A Elbayoumi
Journal:  Int J Nanomedicine       Date:  2016-04-26
View more
  2 in total

Review 1.  Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.

Authors:  Buhle Buyana; Tobeka Naki; Sibusiso Alven; Blessing Atim Aderibigbe
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

2.  Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.

Authors:  Andrea Nicolini; Paola Ferrari; Riccardo Morganti; Angelo Carpi
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.